Neoleukin Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Neurogene

09/08/2022 23:02

* Neoleukin Therapeutics Inc  NLTX.OQ  reported a quarterly
adjusted loss of 28 cents​​ per share for the quarter ended in
June. The mean expectation of seven analysts for the quarter was
for a loss of 30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Neoleukin Therapeutics Inc's reported EPS for the quarter
was a
loss of 28 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Neoleukin Therapeutics Inc shares had risen by 2.9% this
quarter and lost 78.0% so far this year.
    * The company reported a quarterly loss of $15.69 million.
    * Wall Street's median 12-month price target for Neoleukin
Therapeutics Inc is $12.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.30          -0.28          Beat
 Mar. 31 2022      -0.30          -0.28          Beat
 Dec. 31 2021      -0.30          -0.28          Beat
 Sep. 30 2021      -0.28          -0.28          Met